# Candel Therapeutics Stock Plunges 39% as FDA Filing Delayed

> Candel Therapeutics shares dropped 39% after FDA filing for prostate cancer therapy pushed to mid-2027.
- Title: Candel Therapeutics Stock Plunges 39% as FDA Filing Delayed
- Summary: Candel Therapeutics shares dropped 39% after FDA filing for prostate cancer therapy pushed to mid-2027.
- Keywords: candel therapeutics, fda, prostate cancer therapy, biologics license application, nasdaq cadl, stock plunge, markets, BigGo Finance
- Source: BigGo Finance — https://finance.biggo.com/news/fe6f963e-98a0-4e60-85f5-d1a2a7c17b9b
- Author: BigGo Finance
- Published: 2026-11-13T06:05:29+00:00
- Read time: 1 min
- Topics: candel therapeutics, fda, prostate cancer therapy, biologics license application, nasdaq cadl, stock plunge, finance, markets
## Stock Plunge
Candel Therapeutics shares fell 39% in after-hours trading after FDA filing for prostate cancer therapy delayed to mid-2027.
## Financial Results
Company reported third-quarter net loss of $21.9 million, up from $11.3 million a year earlier.
## FDA Timeline Shift
FDA filing for aglatimagene now expected in mid-2027 instead of fourth quarter of 2026.
## Cash Position
Cash of $203.1 million expected to fund operations through second quarter of 2028.
## CEO Statement
CEO Paul Peter Tak said company is well positioned to execute operating plan into Q2 2028.

> We believe we are well positioned to execute our operating plan into Q2 2028
## Key takeaway

Candel Therapeutics stock fell 39% in after-hours trading as FDA filing for prostate cancer therapy delayed to mid-2027.